Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
At the recent Association of Community Cancer Centers’ 40th National Oncology Conference, held October 4-6 in Austin, Texas, Afreen Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, sat down for a conversation with The American Journal of Managed Care® to discuss both the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Here she discusses for whom and in what conditions e-consults are a potential mode of care access.
Transcript
Are there specific patient populations or medical conditions in which e-consults can be particularly beneficial?
I think any area within cancer care can be transformed through e-consults, whether it is psychiatry, psychology care. I think the more niche you are in practice—in the sense that if it is a cardiologist that specializes in cancer therapies and cancer care, or if it is a nephrologist that specializes in cancer therapies and kind of cancer toxicities—depending on what the needs are of the practice, really, defining that and matching that with the experts around the country is where electronic consults can be very helpful. Anywhere where you identify poor access is an opportunity where electronic consults can be very well utilized.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More